Search

Search results

100 results found

Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials

Wykoff, Charles, Francis Abreu, Anthony Adamis, Karen Basu, David Eichenbaum, Zdenka Haskova, Hugh Lin, et al. 2022. “Efficacy, Durability, and Safety of Intravitreal Faricimab With Extended Dosing up to Every 16 Weeks in Patients With Diabetic Macular Oedema (YOSEMITE and RHINE): Two Randomised, Double-Masked, Phase 3 Trials”. Lancet 399 (10326): 741-55.

Reply

Chen, Stephanie, Amee Azad, and Suzann Pershing. 2022. “Reply”. Ophthalmology 129 (2): e33-e35.